Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
作者信息
Jamy Omer, Zhou Fuling, Zeidner Joshua
机构信息
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Department of Hematology, Wuhan University, Wuhan, China.
出版信息
Front Immunol. 2024 Oct 17;15:1501760. doi: 10.3389/fimmu.2024.1501760. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Front Immunol. 2024 Oct 17;15:1501760. doi: 10.3389/fimmu.2024.1501760. eCollection 2024.
2
Immunotherapies in acute leukemia.
Therapie. 2022 Mar-Apr;77(2):241-250. doi: 10.1016/j.therap.2021.12.003. Epub 2021 Dec 6.
3
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against - mutant acute myeloid leukemia and -rearranged acute lymphoblastic leukemia.
Haematologica. 2023 Feb 1;108(2):457-471. doi: 10.3324/haematol.2022.281456.
4
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Front Immunol. 2020 Dec 15;11:580328. doi: 10.3389/fimmu.2020.580328. eCollection 2020.
5
Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials.
Pediatr Blood Cancer. 2019 Aug;66(8):e27700. doi: 10.1002/pbc.27700. Epub 2019 Mar 25.
6
Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
Leuk Lymphoma. 2015 Feb;56(2):472-9. doi: 10.3109/10428194.2014.924118. Epub 2014 Jun 25.
7
Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan.
Pak J Med Sci. 2023 Sep-Oct;39(5):1440-1445. doi: 10.12669/pjms.39.5.6405.
8
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Expert Opin Biol Ther. 2024 Apr;24(4):221-223. doi: 10.1080/14712598.2024.2333793. Epub 2024 Mar 25.
9
Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Arch Pathol Lab Med. 2006 Feb;130(2):153-7. doi: 10.5858/2006-130-153-IOMCAT.
10
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
J Hematol Oncol. 2018 May 2;11(1):60. doi: 10.1186/s13045-018-0603-7.
本文引用的文献
1
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
Front Pharmacol. 2023 Apr 19;14:1151032. doi: 10.3389/fphar.2023.1151032. eCollection 2023.
2
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Leuk Lymphoma. 2021 Sep;62(9):2292-2294. doi: 10.1080/10428194.2021.1897807. Epub 2021 Mar 10.
3
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
4
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Toxins (Basel). 2020 Apr 9;12(4):241. doi: 10.3390/toxins12040241.
5
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.
Front Oncol. 2019 Sep 19;9:917. doi: 10.3389/fonc.2019.00917. eCollection 2019.
Zotero 插件